A breakthrough in life-saving medical technology has arrived. The U.S. Food and Drug Administration (FDA) has officially ...

SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial ...

Wound Care Services in Humble, TX Modern Heart and Vascular Institute Modern Heart and Vascular, a cardiology practice, Now Prov ...

A Durham company secured federal approval for its bioengineered tissue, which could become a revolutionary treatment for ...

The FDA has granted a groundbreaking approval to Humacyte for its off-the-shelf, bioengineered blood vessel implant, designed ...

On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod ...

There is a considerable clinical need for alternatives to the autologous vein and artery tissues used for vascular reconstructive surgeries such as CABG, lower limb bypass, arteriovenous shunts ...

The first acellular tissue engineered vessel for adults with vascular trauma in a bodily extremity has been approved by the U.S. FDA. Symvess, which comes from regenerative tissue developer Humacyte ...

Silver Spring, Md Thursday, December 26, 2024, 11:00 Hrs [IST] ...